Control of CRFs in T2DM patients results in a clinically important reduction in the risk of death and complications related to diabetes.
Objective: To assess the degree of control of modifiable CRFs in treated T2DM patients, stratified by diabetes therapy.
Materials and methods: Cross-sectional study in 574 T2DM patients who attended our clinic for a routine follow-up. Fasting plasma glucose (FPG), HbA1C, HDL-Cholesterol (HDL-Ch), LDL-Ch and triglycerides (TGs), systolic (SBP) and diastolic blood pressure (DBP), BMI, waist circumference (WC), smoking status and cardioprotective medications were extracted from over diet dose. We applied the ADA recommendations for our comparisons. The use of cardioprotective medications was also evaluated.
Results: Mean (±S.D.) age was 67.2±11.4 years. Overall, 43% patients received insulin and 57% took taking oral hypoglycaemic drugs (OHD). Insulin users tended to be older, to have longer duration of diabetes, higher WC, and higher prevalence of obesity, abdominal obesity, metabolic syndrome (MS), coronary artery disease (CAD) and hypertension, than subjects taking OHD. Moreover, had higher BMI (P=0.004), SBP (P=0.002), FPG (P=0.000), and HbA1C (P=0.000), than patients taking OHD. The percentage of subjects who reached the HbA1C and SBP target and the number of male patients who achieved the WC target was higher among subjects taking OHD than in those on insulin (P=0.000, 0.03, 0.016 respectively). More subjects on insulin than on OHD were taking antiplatelet therapy (P=0.001), ACEIs/ARBs (P=0.004), beta-blockers (P=0.0035), calcium channel blockers (P=0.0031) and diuretics (P=0.01).
Conclusions: The higher prevalence of obesity, abdominal obesity, hypertension, CAD and MS, and the poor control of the majority of CVRFs observed in our diabetic population treated with insulin, supports the need for more aggressive arrangement of their CVRFs.
03 - 07 May 2008
European Society of Endocrinology